Heterogeneity in the half-life of factor VIII concentrate in patients with hemophilia A is due to variability in the clearance of endogenous von Willebrand factor
posted on 2023-05-08, 15:19authored byEinas Elsheikh, Michelle LavinMichelle Lavin, Lilian Antunes Heck, Niamh Larkin, Brendan Mullaney, Dearbhla DohertyDearbhla Doherty, Megan Kennedy, Catriona Keenan, Thomas Guest, Brian O'Mahony, Judicael Fazavana, Padraic G Fallon, Roger PrestonRoger Preston, John Gormley, Kevin Ryan, Niamh M O'Connell, Evelyn Singleton, Mary Byrne, Mark McGowan, Sheila Roche, Mairead Doyle, Maeve P Crowley, Susan I O'Shea, Birgit M Reipert, Jill M Johnsen, Steven W Pipe, Jorge Di Paola, Peter L Turecek, James O'DonnellJames O'Donnell, iPATH study group
<p><strong>Background:</strong> Previous studies have reported marked interindividual variation in factor VIII (FVIII) clearance in patients with hemophilia (PWH) and proposed a number of factors that influence this heterogeneity.</p>
<p><strong>Objectives:</strong> To investigate the importance of the clearance rates of endogenous von Willebrand factor (VWF) compared with those of other FVIII half-life modifiers in adult PWH.</p>
<p><strong>Methods:</strong> The half-life of recombinant FVIII was determined in a cohort of 61 adult PWH. A range of reported modifiers of FVIII clearance was assessed (including plasma VWF:antigen and VWF propeptide levels; VWF-FVIII binding capacity; ABO blood group; and nonneutralizing anti-FVIII antibodies). The FVIII-binding region of the VWF gene was sequenced. Finally, the effects of variation in FVIII half-life on clinical phenotype were investigated.</p>
<p><strong>Results:</strong> We demonstrated that heterogeneity in the clearance of endogenous plasma VWF is a key determinant of variable FVIII half-life in PWH. Both ABO blood group and age significantly impact FVIII clearance. The effect of ABO blood group on FVIII half-life in PWH is modulated entirely through its effect on the clearance rates of endogenous VWF. In contrast, the age-related effect on FVIII clearance is, at least in part, VWF independent. In contrast to previous studies, no major effects of variation in VWF-FVIII binding affinity on FVIII clearance were observed. Although high-titer immunoglobulin G antibodies (≥1:80) were observed in 26% of PWH, these did not impact FVIII half-life. Importantly, the annual FVIII usage (IU/kg/y) was significantly (p = .0035) increased in patients with an FVIII half-life of <12 hours.</p>
<p><strong>Conclusion:</strong> Our data demonstrate that heterogeneity in the half-life of FVIII concentrates in patients with hemophilia A is primarily attributable to variability in the clearance of endogenous VWF.</p>
Funding
Science Foundation (SFI) under the SFI Strategic Partnership Programme Grant number 16/SPP3303
Shire US Inc., a member of the Takeda group of companies, Lexington, Massachusetts.
National Institutes of Health for the Zimmerman Program (HL081588)
Science Foundation Ireland Frontiers for the Future (FFP) Award (20/FFP-A/8952)
The original article is available at https://www.sciencedirect.com/
Published Citation
Elsheikh E, et al. Heterogeneity in the half-life of factor VIII concentrate in patients with hemophilia A is due to variability in the clearance of endogenous von Willebrand factor. J Thromb Haemost. 2023;21(5):1123-1134.